entertainment -WSS

entertainment

author：hotspot 2025-10-01 17:21:23 - browse：6

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Community addresses injustice for Long Island mothers

WSS

Listen: Biogen's messy board & Laronde's data problem

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Connecting traumatic brain injury and domestic violence

Brain 'hot spot' may explain why African Americans feel greater pain

Snackable artificial intelligence, expert AI, and the pharma industry

'Make People Better': The CRISPR babies story you probably don't know

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Listen: PBM conflicts, RSV vaccines, & the future of flu season

The cancer drug shortage isn’t new — and neither are the solutions

A new study asks: Are we harming blood donors by taking blood?

How one medical school became remarkably diverse

Crinetics acromegaly drug succeeds in late

New air purifier tech could be key to improving indoor air quality

RaDonda Vaught case: a double standard for nurses, physicians

Jerome Adams on the need for new antivirals for Covid

Meta looks to target Twitter with a rival app called Threads

focus

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

ALS advocates say criticism of new drugs misses bigger picture

Doctor appointment wait times are getting worse

Meta looks to target Twitter with a rival app called Threads

Ethical issues complicate the benefits of medical crowdfunding

Ethical issues complicate the benefits of medical crowdfunding

focus

focus

explore

Wikipedia